Pharm Exec Podcast
Pharmaceutical Executive Daily: FDA's new Fast-Track Review
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:02:49
- Mas informaciones
Informações:
Sinopsis
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.
